Arcus Biosciences
Arcus Biosciences develops differentiated molecules and combination therapies for cancer treatment, with a clinical pipeline that includes domvanalimab, etrumadenant, and zimberelimab. The company partners with Gilead Sciences and Taiho Pharmaceutical and conducts global clinical trials in various cancer types.
Arcus Biosciences Services
Arcus Biosciences develops differentiated molecules and combination therapies aimed at treating cancer. The company conducts global clinical trials for its investigational products, encompassing a wide array of cancer types, including lung, gastrointestinal, and kidney cancers. Arcus Biosciences also offers an Expanded Access Program to provide investigational therapies to eligible patients outside the scope of their clinical trials.
Arcus Biosciences Products
Arcus Biosciences has a clinical pipeline that includes molecules such as domvanalimab, etrumadenant, and zimberelimab. These investigational products are designed to target mechanisms like TIGIT, PD-1, CD39, and AXL, with the goal of providing effective treatment options for various forms of cancer.
Arcus Biosciences Partnerships
Arcus Biosciences engages in strategic partnerships to enhance its development and commercialization efforts. Notably, the company has a 10-year partnership with Gilead Sciences focused on cancer immunotherapies. Additionally, Arcus collaborates with Taiho Pharmaceutical to advance the development of its therapies in Japan and other Asian territories.
Arcus Biosciences Headquarters and Facilities
Arcus Biosciences is headquartered in Hayward, California, and has additional facilities in Brisbane, California. These locations support the company's research, development, and clinical trial operations, enabling them to advance their innovative cancer treatments.
Arcus Biosciences Clinical Trials
Arcus Biosciences conducts clinical trials across various cancer types, including lung, gastrointestinal, and kidney cancers. These trials involve the company's investigational molecules, such as domvanalimab, etrumadenant, and zimberelimab, and are conducted on a global scale. The trials aim to evaluate the safety and efficacy of these treatments in addressing unmet medical needs in oncology.